Basic Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Oct 21, 2015; 21(39): 11127-11140
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11127
Table 1 Demographic features and clinicopathologic correlation of fibulin-5 in patients with hepatocellular carcinoma
ParameterTotal No. of patients(n = 140)FBLN-5 expression
P value1
High (n= 93)Low (n = 47)
Age (yr)< 505440140.211
≥ 50865531
GenderMale11379340.287
Female271611
Tumor size (cm)< 58257250.618
≥ 5583820
No. of tumor nodules112287350.0232
≥ 218810
Recurrent CancerAbsent8764230.064
Present533122
CirrhosisAbsent5029210.063
Present906624
Serum AFP levelNegative7952270.558
Positive614318
HBVHBsAg (-)3222100.902
HBsAg (+)1087335
TNM tumor stageI + II10279230.0012
III + IV381622
BCLC tumor stage0 + A9374190.0012
B + C + D472126
Table 2 Disease-specific survival by Cox regression analysis between the subgroups of various clincopathological parameters
ParameterNo.No. of eventsHR (95%CI)1P value2
Age (yr)< 5054180.373 (0.169-0.823)0.158
≥ 508624
GenderMale113300.864 (0.324-2.306)0.771
Female2712
Tumor size (cm)< 582231.874 (0.902-3.895)0.093
≥ 55819
No. of tumor nodules1122323.634 (1.481-8.916)0.0053
≥ 21810
Recurrent cancerAbsent87150.587 (0.231-1.491)0.263
Present5328
CirrhosisAbsent50140.924 (0.426-2.004)0.841
Present9029
Serum AFP levelNegative79210.615 (0.280-1.352)0.227
Positive6121
HBVHBsAg (-)32111.487 (0.670-3.302)0.329
HBsAg (+)10831
TNM tumor stageI + II102117.478 (2.571-21.753)0.0013
III + IV3831
BCLC tumor stage0 + A9385.257 (1.707-16.186)0.0043
B + C + D4734
FBLN-5 ExpressionHigh95134.276 (2.033-8.995)0.0013
Low4529